DEA

Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.

Retrieved on: 
Thursday, March 7, 2024

GRANTS, NM, March 07, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation, a Delaware corporation (the “Company”), announced today the submission of its DEA Registration for Bulk Production of Schedule I and Schedule II Controlled Substances. The application is an official and substantial step in Bright Green's expansion into the legal manufacturing of plant-based controlled substances including psilocybin, peyote, ibogaine, coca leaves, and opium poppy, alongside their active pharmaceutical ingredients ("API") for medical, research, and other legal purposes. The move aligns with Bright Green's commitment to providing a domestic supply of essential medications, addressing critical concerns associated with disruptions to the global pharmaceutical supply chain, and the national security risk currently posed by the United States’ dependency on imports.

Key Points: 
  • GRANTS, NM, March 07, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation, a Delaware corporation (the “Company”), announced today the submission of its DEA Registration for Bulk Production of Schedule I and Schedule II Controlled Substances.
  • Last year, Bright Green obtained its DEA Registration for the Bulk Manufacturing of Cannabis, a Schedule I Controlled Substance, and recently received approval from the New Mexico Board of Pharmacy to produce additional Schedule I and Schedule II Controlled Substances.
  • The Company has assembled a team of experienced professionals to lead its controlled substance production efforts, ensuring adherence to stringent security and compliance standards.
  • The submission of this registration marks a significant milestone for Bright Green Corporation as it pioneers the “Drugs Made in America” movement.

BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS

Retrieved on: 
Thursday, February 22, 2024

GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) company announced today that final approval has been received from the New Mexico Board of Pharmacy and the DEA for unique licensing that allows Bright Green to register, license, and authorize Schedule I and Schedule II plant-based drugs and Active Pharmaceutical Ingredients (APIs) for research, production, and manufacturing purposes. Schedule I Substances include Psilocybin, psilocybin, mescaline, peyote, ibogaine Schedule II Substances: Opium, poppy straw, raw opium, opium extracts, powdered opium, granulated opium, tincture of opium, opium fluid extracts, opium straw concentrates, pending: erythroxylon coca (cocaine)

Key Points: 
  • Achieving this substantial approval allows Bright Green to bring their deep expertise to these issues to help propel our Drugs Made in America movement forward.
  • The research will be conducted the Company’s C2 team in Albuquerque, New Mexico, and the reshoring of production and manufacturing to the U.S. will take place at the company’s Grants, New Mexico facility.
  • Medical plants will be produced in climate-controlled glass greenhouses engineered to ensure quality and predictability, laying a roadmap for guaranteed supply contracts with both federal government entities and other pharmaceutical interests.
  • Bright Green expects to be the first company in almost 100 years to produce, manufacture and supply API for Schedule I and Schedule II controlled substances and to deliver on contracts of this type.

Easterly Government Properties Awarded Lease to Develop 50,777 RSF Federal Courthouse in Flagstaff, Arizona

Retrieved on: 
Monday, March 4, 2024

Easterly Government Properties, Inc. (NYSE: DEA) (“Easterly”), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced today that it has been awarded a 20-year non-cancelable lease for a 50,777 rentable square foot Federal courthouse in Flagstaff, Arizona (“JUD - Flagstaff”).

Key Points: 
  • Easterly Government Properties, Inc. (NYSE: DEA) (“Easterly”), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced today that it has been awarded a 20-year non-cancelable lease for a 50,777 rentable square foot Federal courthouse in Flagstaff, Arizona (“JUD - Flagstaff”).
  • View the full release here: https://www.businesswire.com/news/home/20240304846914/en/
    Easterly Government Properties, Inc. (NYSE: DEA) was awarded a lease to develop a 50,777 RSF federal courthouse in Flagstaff, Arizona.
  • Once complete, a 20-year non-cancelable lease will commence with the United States Government.
  • “We believe being awarded a 20-year non-cancelable lease in exchange for delivering a state-of-the-art, mission-critical courthouse represents our recognized definable edge in our ability to develop in this specialized market.

Easterly Government Properties to Participate in the Citi 2024 Global Property CEO Conference

Retrieved on: 
Thursday, February 29, 2024

Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced today that management will present at the Citi 2024 Global Property CEO Conference (the “Conference”) in Hollywood, Florida on Monday, March 4, 2024, at 8:10 AM Eastern Time.

Key Points: 
  • Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, announced today that management will present at the Citi 2024 Global Property CEO Conference (the “Conference”) in Hollywood, Florida on Monday, March 4, 2024, at 8:10 AM Eastern Time.
  • For investors interested in listening to the presentation, a live audio-webcast in listen-only mode will be provided in the Presentation section of the Company’s Investor Relations website at ir.easterlyreit.com .
  • A replay of the webcast will be available through September 30, 2024.
  • Electronic copies of any materials to be provided to investors at the Conference will also be made available in the Presentation section of the Company’s Investor Relations website prior to the start of the Conference.

Easterly Government Properties Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 27, 2024

Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, today announced its results of operations for the quarter and full year ended December 31, 2023.

Key Points: 
  • Easterly Government Properties, Inc. (NYSE: DEA) (the “Company” or “Easterly”), a fully integrated real estate investment trust (“REIT”) focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government, today announced its results of operations for the quarter and full year ended December 31, 2023.
  • In addition, the Company wholly owned one property under re-development that the Company expects will encompass approximately 0.2 million rentable square feet upon completion.
  • As of December 31, 2023, the portfolio had a weighted average age of 14.6 years, based upon the date properties were built or renovated-to-suit, and had a weighted average remaining lease term of 10.5 years.
  • On February 21, 2024, the Board of Directors of Easterly approved a cash dividend for the fourth quarter of 2023 in the amount of $0.265 per common share.

PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape

Retrieved on: 
Friday, February 23, 2024

Germany is expected to pass the Cannabis Act today (Friday), heralding a transformative era for the medical cannabis industry.

Key Points: 
  • Germany is expected to pass the Cannabis Act today (Friday), heralding a transformative era for the medical cannabis industry.
  • The passage of the Cannabis Act represents a pivotal shift, primarily by making it substantially easier and more cost-effective for doctors to prescribe medical cannabis.
  • The Act's facilitation of the prescription process is anticipated to lead to a surge in demand for medical cannabis.
  • Looking ahead, Germany's Cannabis Act marks a significant milestone for the medical cannabis industry, promising to increase demand, expand the patient base, and reduce prices through heightened competition.

Easterly Government Properties Announces Quarterly Dividend

Retrieved on: 
Thursday, February 22, 2024

Easterly Government Properties, Inc. (NYSE: DEA), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to U.S. Government agencies, announced today that its Board of Directors has approved a quarterly cash dividend of $0.265 per common share.

Key Points: 
  • Easterly Government Properties, Inc. (NYSE: DEA), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to U.S. Government agencies, announced today that its Board of Directors has approved a quarterly cash dividend of $0.265 per common share.
  • The dividend will be payable on March 18, 2024 to shareholders of record on March 6, 2024.
  • *Anticipated annual dividend yield on investment is based on DEA’s closing stock price on the NYSE on February 20, 2024, and an annualized quarterly cash dividend of $0.265 per common share.

VerifiNow Launches PatientVerifi, A Patient Identity Verification Solution for Telehealth Providers

Retrieved on: 
Monday, February 26, 2024

PASADENA, Calif., Feb. 26, 2024 /PRNewswire-PRWeb/ -- As the demand for telehealth services surges, VerifiNow announces the launch of PatientVerifi at the ViVE Digital Health Conference in Los Angeles. PatientVerifi is an advanced solution to meet the increasingly crucial need for secure patient identity verification in virtual healthcare.

Key Points: 
  • PatientVerifi is an advanced solution to meet the increasingly crucial need for secure patient identity verification in virtual healthcare.
  • Telehealth's exponential growth necessitates a parallel evolution in patient identity verification.
  • PatientVerifi ensures the patient behind the screen is verified and authenticated with the highest accuracy, preserving the integrity of healthcare services.
  • These requirements are part of the DEA's efforts to maintain patient safety while allowing the convenience of telehealth to support patient care.

Vencanna Announces Amended Definitive Agreement with The Cannavative Group, Completion of Name Change, Resumption of Trading and Operational Update

Retrieved on: 
Friday, February 23, 2024

Pursuant to the Amended Agreement, Vencanna will acquire all of the outstanding membership units of Cannavative through an all-share exchange.

Key Points: 
  • Pursuant to the Amended Agreement, Vencanna will acquire all of the outstanding membership units of Cannavative through an all-share exchange.
  • The exchangeable securities are exchangeable, at the option of the holder, on a one-for-one basis for equivalent securities of Vencanna.
  • On January 17, 2023, at an annual general and special meeting, the shareholders of Vencanna approved the name change.
  • The Company has engaged Independent Trading Group (ITG) Inc. to act as the broker through which the Bid will be conducted.

Nitazenes are a powerful class of street drugs emerging across the US

Retrieved on: 
Thursday, February 15, 2024

Researchers have relatively little information on how the human body reacts to nitazenes because the drugs have never gone through clinical trials.

Key Points: 
  • Researchers have relatively little information on how the human body reacts to nitazenes because the drugs have never gone through clinical trials.
  • As law enforcement has cracked down on other drugs such as fentanyl, illegal labs have used historical pharmacology research to formulate analogs of nitazenes as street drugs.
  • Although nitazenes are now identified as illegal street drugs in numerous countries, many medical providers aren’t even aware they exist.
  • Nitazenes are also mixed with other street drugs such as heroin and fentanyl and with fake oxycodone pills, without users knowing it.